tropsium chloride/xanomeline (Cobenfy, KarXT)
Jump to navigation
Jump to search
Indications
- treatment of schizophrenia[1] FDA-approved[2]
- investigational treatment of Alzheimer's disease[3]
Dosage
- twice daily titrated to effect
- maximum daily dose: 250 mg of xanomeline & 60 mg of trospium
More general terms
Components
References
- ↑ 1.0 1.1 Brannan SK, Sawchak S, Miller AC et al Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia. N Engl J Med 2021; 384:717-726 Feb 25 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33626254 https://www.nejm.org/doi/full/10.1056/NEJMoa2017015B
- ↑ 2.0 2.1 Brooks M FDA OKs First-in-Class Antipsychotic for Schizophrenia. Medscape. Sept 27, 2024 https://www.medscape.com/viewarticle/fda-oks-first-class-antipsychotic-schizophrenia-2024a1000hno
- ↑ 3.0 3.1 Kwon D New schizophrenia drug could treat Alzheimer's disease. Nature News. 2024. Nov 21. https://www.nature.com/articles/d41586-024-03707-5?utm_source=Live+Audience&utm_campaign=1395f3bf68-nature-briefing-daily-20241121&utm_medium=email&utm_term=0_b27a691814-1395f3bf68-51070072
Tobin AB A golden age of muscarinic acetylcholine receptor modulation in neurological diseases. Nature Reviews Drug Discovery. 2024. 23:743-758 PMID: https://www.ncbi.nlm.nih.gov/pubmed/39143241 https://www.nature.com/articles/s41573-024-01007-1